[ad_1]
According to the American newspaper “New York Times”, this drug injection, which is administered once every two months, replaces the pill that is taken daily.
And because this injection showed results that were described as promising among women, the researchers decided to stop clinical trials, in preparation for the issue of manufacturing and commercialization.
Although prevention currently requires taking one pill on a daily basis, or 365 per year, it is expected to become easier with only 6 injections per year if the new treatment is approved.
Sigal Yawitz, a women’s health expert at a Boston hospital, said this injection represents “a fundamental change for women.”
And in 2019, data released by the United Nations revealed that girls and women make up nearly half of people infected with HIV.
In sub-Saharan Africa, girls make up more than 80% of all HIV carriers between the ages of 15 and 19.
But the use of this injection in developing countries in the future requires it to be accessible and inexpensive, so that it is accessible to people.
A controversy arose years ago about the use of anti-AIDS drugs in order to protect healthy people from HIV infection.
And some women are reluctant to take the pill, because the question repeats itself daily and it could be embarrassing for them.
Also, some women find themselves having to discuss taking the pill with their partner or husband.
Clinical trials of the injection were conducted by the HIV Prevention Trials Network, a global initiative funded by the US National Institutes of Health.
This study compared the injection, which is called “capotgraver”, and the drug known as “Truvada”, with a sample of 3,223 participants in seven sub-Saharan African countries.
The study found that 34 participants who took the drug “Truvada” were infected with AIDS during the clinical trial phase, while 6 women were infected among those who received the injection.
The data indicated that two out of six infected women had stopped taking the dose, which means that the injection is very effective.
.
[ad_2]
Source link
